DECIPHERING THE MOLECULAR LANDSCAPE OF HEAD AND NECK SQUAMOUS CELL CARCINOMA: COMPREHENSIVE ANALYSIS OF SLC31A1 EXPRESSION AND REGULATORY MECHANISMS

Main Article Content

Asim Gamaryani
Fadia Waheed
Ammar Nawazish
Sanobar Gull
Habibullah Janyaro
Bushra Parveen
Murtaza Haider
Momina Sami Khan
Syed Meesam Raza
Jamal Muhammad Khan

Keywords

SLC31A1, HNSC, Expression analysis, Biomarker

Abstract

In the pursuit of understanding the intricate molecular landscape of Head and Neck Squamous Cell Carcinoma (HNSC), this study conducts a comprehensive analysis of the expression and regulatory mechanisms of SLC31A1. Initially focusing on overall expression, we uncover a significant up-regulation of SLC31A1 in HNSC tissues compared to normal controls, indicating its potential role in HNSC progression. Subsequent investigations, stratified based on various parameters, reveal consistent overexpression patterns across different cancer stages, patient ages, genders, and racial backgrounds, underscoring the substantial involvement of SLC31A1 in HNSC progression. Expanding our exploration into SLC31A1's regulatory mechanisms, we delve into its promoter methylation status. The analysis uncovers hypo-methylation in HNSC samples, suggesting a correlation with its overexpression in the disease context. Further investigations based on different parameters reveal persistent hypo-methylation patterns, emphasizing the pivotal role of SLC31A1 in HNSC progression. In a critical survival analysis, higher expression levels of SLC31A1 are associated with poor prognosis in HNSC patients. This comprehensive examination provides valuable insights into the potential diagnostic and therapeutic implications of SLC31A1 in HNSC.

Abstract 132 | pdf Downloads 68

References

1. Li Q, Tie Y, Alu A, Ma X, Shi H. Targeted therapy for head and neck cancer: signaling pathways and clinical studies. Signal Transduction and Targeted Therapy. 2023;8(1):31.
2. Choi S-Y, Cheong H-K, Lee M-K, Kang J-W, Lee Y-C, Oh I-H, et al. Metabolic Diseases and Risk of Head and Neck Cancer: A Cohort Study Analyzing Nationwide Population-Based Data. Cancers. 2022;14(13):3277.
3. Schicho A, Habicher W, Wendl C, Stroszczynski C, Strotzer Q, Dollinger M, et al. Clinical Value of Diffusion-Weighted Whole-Body Imaging with Background Body Signal Suppression (DWIBS) for Staging of Pat1. Li Q, Tie Y, Alu A, Ma X, Shi H. Targeted therapy for head and neck cancer: signaling pathways and clinical studies. Signal Transduction and Targeted Therapy. 2023 2023/01/16;8(1):31.
2. Usman M, Hameed Y, Ahmad M. Does human papillomavirus cause human colorectal cancer? Applying Bradford Hill criteria postulates. ecancermedicalscience. 2020;14.
3. Choi S-Y, Cheong H-K, Lee M-K, Kang J-W, Lee Y-C, Oh I-H, et al. Metabolic Diseases and Risk of Head and Neck Cancer: A Cohort Study Analyzing Nationwide Population-Based Data. Cancers. 2022;14(13):3277.
4. Schicho A, Habicher W, Wendl C, Stroszczynski C, Strotzer Q, Dollinger M, et al. Clinical Value of Diffusion-Weighted Whole-Body Imaging with Background Body Signal Suppression (DWIBS) for Staging of Patients with Suspected Head and Neck Cancer. Tomography. 2022;8(5):2522-32.
5. Ahmad M, Khan M, Asif R, Sial N, Abid U, Shamim T, et al. Expression Characteristics and Significant Diagnostic and Prognostic Values of ANLN in Human Cancers. International Journal of General Medicine. 2022:1957-72.
6. Ribeiro IP, Esteves L, Caramelo F, Carreira IM, Melo JB. Integrated Multi-Omics Signature Predicts Survival in Head and Neck Cancer. Cells. 2022;11(16):2536.
7. Kong F-S, Ren C-Y, Jia R, Zhou Y, Chen J-H, Ma Y. Systematic pan-cancer analysis identifies SLC31A1 as a biomarker in multiple tumor types. BMC medical genomics. 2023;16(1):61.
8. Qi Y, Yao Q, Li X, Li X, Zhang W, Qu P. Cuproptosis-related gene SLC31A1: prognosis values and potential biological functions in cancer. Scientific Reports. 2023;13(1):17790.
9. Zhang P, Yang H, Zhu K, Chang C, Lv W, Li R, et al. SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer. Biomedicines. 2023;11(11):2884.
10. Wang X, Zhou M, Liu Y, Si Z. Cope with copper: From copper linked mechanisms to copper-based clinical cancer therapies. Cancer Lett. 2023 May 1;561:216157.
11. Wu G, Peng H, Tang M, Yang M, Wang J, Hu Y, et al. ZNF711 down-regulation promotes CISPLATIN resistance in epithelial ovarian cancer via interacting with JHDM2A and suppressing SLC31A1 expression. EBioMedicine. 2021 Sep;71:103558.
12. Ren F, Logeman BL, Zhang X, Liu Y, Thiele DJ, Yuan P. X-ray structures of the high-affinity copper transporter Ctr1. Nature Communications. 2019 2019/03/27;10(1):1386.
13. Huo S, Wang Q, Shi W, Peng L, Jiang Y, Zhu M, et al. ATF3/SPI1/SLC31A1 Signaling Promotes Cuproptosis Induced by Advanced Glycosylation End Products in Diabetic Myocardial Injury. International Journal of Molecular Sciences. 2023;24(2):1667.
14. Xu W, Li H, Hameed Y, Abdel-Maksoud MA, Almutairi SM, Mubarak A, et al. Elucidating the clinical and immunological value of m6A regulator-mediated methylation modification patterns in adrenocortical carcinoma. Oncology Research. 2023;31(5):819.
15. Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020 Jul 2;48(W1):W509-w14.
16. Usman M, Hameed Y, Ahmad M. Does epstein–barr virus participate in the development of breast cancer? A brief and critical review with molecular evidences. 2020.
17. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017 Aug;19(8):649-58.
18. Stanisz A. Przystępny kurs statystyki w oparciu o program STATISTICA PL na przykładach z medycyny: StatSoft Polska; 1998.
19. Usman M, Hameed Y. GNB1, a novel diagnostic and prognostic potential biomarker of head and neck and liver hepatocellular carcinoma. Journal of Cancer Research and Therapeutics. 9000.
20. McCleary-Wheeler AL, Lomberk GA, Weiss FU, Schneider G, Fabbri M, Poshusta TL, et al. Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis. Cancer letters. 2013;328(2):212-21.
21. Usman M, Hameed Y, Ahmad M, Rehman JU, Ahmed H, Hussain MS, et al. Breast cancer risk and human papillomavirus infection: a Bradford Hill criteria based evaluation. Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders). 2022;22(4):41-50.
22. Zhu X, Tang L, Mao J, Hameed Y, Zhang J, Li N, et al. Decoding the mechanism behind the pathogenesis of the focal segmental glomerulosclerosis. Computational and Mathematical Methods in Medicine.2022.
23. Mao J, Huang X, Okla MK, Abdel-Maksoud MA, Mubarak A, Hameed Z, et al. Risk Factors for TERT promoter mutations with papillary thyroid carcinoma patients: a meta-analysis and systematic review. Computational and Mathematical Methods in Medicine.2022.
24. Hameed Y, Usman M, Liang S, Ejaz S. Novel diagnostic and prognostic biomarkers of colorectal cancer: capable to overcome the heterogeneity-specific barrier and valid for global applications. Plos one. 2021;16(9):e0256020.
25. Yasir M, Nawaz A, Ghazanfar S, Okla M, Chaudhary A, Al WH, et al. Anti-bacterial activity of essential oils against multidrug-resistant foodborne pathogens isolated from raw milk. Brazilian Journal of Biology. 2022;84:e259449.
26. Ullah L, Hameed Y, Ejaz S, Raashid A, Iqbal J, Ullah I, et al. Detection of novel infiltrating ductal carcinoma-associated BReast CAncer gene 2 mutations which alter the deoxyribonucleic acid-binding ability of BReast CAncer gene 2 protein. Journal of Cancer Research and Therapeutics. 2020;16(6):1402-7.
27. Zhang L, Sahar A, Li C, Chaudhary A, Yousaf I, Saeedah M, et al. A detailed multi-omics analysis of GNB2 gene in human cancers. Brazilian Journal of Biology. 2022;84.
28. Khalil T, Okla M, Al-Qahtani W, Ali F, Zahra M, Shakeela Q, et al. Tracing probiotic producing bacterial species from gut of buffalo (Bubalus bubalis), South-East-Asia. Brazilian Journal of Biology. 2022;84:e259094.
29. Hameed Y, Ejaz S. TP53 lacks tetramerization and N-terminal domains due to novel inactivating mutations detected in leukemia patients. Journal of Cancer Research and Therapeutics. 2021;17(4):931-7.
30. Khan M, Hameed Y. Discovery of novel six genes-based cervical cancer-associated biomarkers that are capable to break the heterogeneity barrier and applicable at the global level. Journal of Cancer Research and Therapeutics. 9000.
31. Välk K, Vooder T, Kolde R, Reintam M-A, Petzold C, Vilo J, et al. Gene expression profiles of non-small cell lung cancer: survival prediction and new biomarkers. Oncology. 2011;79(3-4):283-92.
32. Jenssen T-K, Kuo W, Stokke T, Hovig E. Associations between gene expressions in breast cancer and patient survival. Human genetics. 2002;111:411-20.

Most read articles by the same author(s)

1 2 > >>